low dose glp 1 agonist GLP-1s GLP-1 receptor agonists Doses available

Summary Although GLP-1R agonists were originally developed for glycemic control in DM, their mechanistic versatility has enabled broader application across a spectrum of cardiovascular, cerebrovascular and metabolic disorders

Mechanism Although the exact mechanisms underlying GLP-1 RA-induced diabetic retinopathy remain unclear, several hypotheses have been proposed

As a GLP-1 receptor agonist, it regulates appetite and improves blood sugar control, making it suitable for those with obesity or related health issues

This study showed a mean weight reduction of 10%, and significant reductions in triglyceride, total cholesterol, and LDL-C levels of 25%, 11%, and 11% respectively [32]

Berberine is the clearest example in human clinical trials

The reduction in LFC was significantly correlated ( p 0.0006) with baseline LFC ( = 0.71), reductions in visceral adipose tissue (VAT) ( = 0.29), reductions in the transaminase liver enzyme ASAT ( = 033), and reductions in body weight ( p = 034) in the tirzepatide groups (54, 79)